Hostname: page-component-77c89778f8-rkxrd Total loading time: 0 Render date: 2024-07-17T15:43:11.722Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of resveratrol in male urogenital tract dysfunctions: an evaluation of pre-clinical data

Published online by Cambridge University Press:  15 November 2021

FB Calmasini Open the ORCID record for FB Calmasini [Opens in a new window] ,
FH Silva ,
EC Alexandre  and
E Antunes
FB Calmasini*
Affiliation:
Department of Structural and Functional Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil
FH Silva
Affiliation:
Laboratory of Multidisciplinary Research, São Francisco University (USF), Bragança Paulista, SP, Brazil
EC Alexandre
Affiliation:
Department of Pharmacology, Faculty of Medical Science, University of Campinas (UNICAMP), Campinas, SP, Brazil
E Antunes
Affiliation:
Department of Pharmacology, Faculty of Medical Science, University of Campinas (UNICAMP), Campinas, SP, Brazil
*
*Corresponding author: Fabiano Beraldi Calmasini; email: fabiano.b.calmasini@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Resveratrol is a polyphenol found naturally in fruits and plants. Recently, studies in humans and animal models have suggested beneficial properties of this polyphenol, such as improvements to metabolic and lipid profiles, along with antioxidant, anti-inflammatory and anti-proliferative effects. In the urogenital tract (UGT), resveratrol has also been tested clinically and experimentally as a therapeutic drug in several diseases; however, the translational efficacy of resveratrol, especially in UGT, is still a matter of debate. In the present review, we address the pre-clinical efficacy of resveratrol in UGT-related dysfunctions, focusing on lower urinary tract symptoms, non-cancerous prostatic disease (benign prostatic hyperplasia and prostatitis) and erectile dysfunction. In vitro studies indicate that resveratrol reduces inflammatory markers and oxidative stress, and improves endothelial function in UGT organs and cells isolated from humans and animals. Despite displaying low oral bioavailability, in vivo administration of resveratrol largely improves erectile dysfunction, benign prostatic hyperplasia, prostatitis and voiding impairments, as evidenced in different animal models. Resveratrol also acts as a microbiota modulator, which may explain some of its beneficial effects in vivo. In contrast to the large amount of pre-clinical data, there are insufficient clinical trials to establish resveratrol treatment efficacy in human UGT-related diseases. In summary, we provide an overview of the in vivo and in vitro efficacy of resveratrol in animal and human UGT dysfunctions, which may support future clinical trials.

Keywords

Prostatic diseasesLower urinary tractErectile dysfunctionPolyphenol
Type
Review Article
Information
Nutrition Research Reviews , Volume 36 , Issue 1 , June 2023 , pp. 86 - 97
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Nutrition Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cooper, K, Chopra, M & Thurnham, D (2004) Wine polyphenols and promotion of cardiac health. Nutr Res Rev 17, 111–130.CrossRefGoogle ScholarPubMed
Nunes, S, Danesi, F, Del Rio, D, et al. (2018) Resveratrol and inflammatory bowel disease: the evidence so far. Nutr Res Rev 31, 85–97.CrossRefGoogle ScholarPubMed
Gambini, J, Ingles, M, Olaso, G, et al. (2015) Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev 2015, 837042.CrossRefGoogle ScholarPubMed
van der Spuy, WJ & Pretorius, E (2009) Is the use of resveratrol in the treatment and prevention of obesity premature? Nutr Res Rev 22, 111–117.CrossRefGoogle ScholarPubMed
Timmers, S, Hesselink, MK & Schrauwen, P (2013) Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci 1290, 83–89.CrossRefGoogle ScholarPubMed
Matsuda, Y, Kobayashi, F, Fukura, F, et al. (2021) Which happens earlier, lower urinary tract symptoms or erectile dysfunction? Sex Med 9, 100275.CrossRefGoogle ScholarPubMed
Nakamura, M, Fujimura, T, Nagata, M, et al. (2012) Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires. Aging Male 15, 111–114.CrossRefGoogle ScholarPubMed
Calogero, AE, Burgio, G, Condorelli, R, et al. (2019) Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male 22, 12–19.CrossRefGoogle ScholarPubMed
Speich, JE, Tarcan, T, Hashitani, H, et al. (2020) Are oxidative stress and ischemia significant causes of bladder damage leading to lower urinary tract dysfunction? Report from the ICI-RS 2019. Neurourol Urodyn 39, Suppl. 3, S16–S22.CrossRefGoogle ScholarPubMed
Bostanci, Y, Kazzazi, A, Momtahen, S, et al. (2013) Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 23, 5–10.CrossRefGoogle ScholarPubMed
Alexandre, EC, Calmasini, FB, de Oliveria, MG, et al. (2016) Chronic treatment with resveratrol improves overactive bladder in obese mice via antioxidant activity. Eur J Pharmacol 788, 29–36.CrossRefGoogle ScholarPubMed
Alexandre, EC, Calmasini, FB, Sponton, ACDS, et al. (2018) Influence of the periprostatic adipose tissue in obesity-associated mouse urethral dysfunction and oxidative stress: effect of resveratrol treatment. Eur J Pharmacol 836, 25–33.CrossRefGoogle ScholarPubMed
Silva, FH, Lanaro, C, Leiria, LO, et al. (2014) Oxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosum. Am J Physiol Heart Circ Physiol 307, H1393–H1400.CrossRefGoogle ScholarPubMed
Calmasini, FB, de Oliveira, MG, Alexandre, EC, et al. (2018) Obesity-induced mouse benign prostatic hyperplasia (BPH) is improved by treatment with resveratrol: implication of oxidative stress, insulin sensitivity and neuronal growth factor. J Nutr Biochem 55, 53–58.CrossRefGoogle Scholar
Chow, SE, Hshu, YC, Wang, JS, et al. (2007) Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 102, 1520–1527.CrossRefGoogle ScholarPubMed
Spanier, G, Xu, H, Xia, N, et al. (2009) Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 60, 111–116.Google ScholarPubMed
Vaquero, A, Scher, M, Erdjument-Bromage, H, et al. (2007) Sirt1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature 450, 440–444.CrossRefGoogle ScholarPubMed
Nikolai, S, Pallauf, K, Huebbe, P, et al. (2015) Energy restriction and potential energy restriction mimetics. Nutr Res Rev 28, 100–120.CrossRefGoogle ScholarPubMed
Calmasini, FB, Silva, FH, Alexandre, EC, et al. (2016) Implication of Rho-kinase and soluble guanylyl cyclase enzymes in prostate smooth muscle dysfunction in middle-aged rats. Neurourol Urodyn 36, 589–596.CrossRefGoogle ScholarPubMed
Calmasini, FB, Leiria, LO, Alves-Junior, MJ, et al. (2015) Increased Rho-kinase-mediated prostate contractions associated with impairment of beta-adrenergic-cAMP-signaling pathway by chronic nitric oxide deficiency. Eur J Pharmacol 758, 24–30.CrossRefGoogle ScholarPubMed
Xiong, Y, Zhang, Y, Tan, J, et al. (2021) The association between metabolic syndrome and lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging male: evidence based on propensity score matching. Transl Androl Urol 10, 384–396.CrossRefGoogle Scholar
Steers, WD (2009) Food for thought: obesity as the major contributing factor for most urological disorders. J Urol 181, 1983–1984.CrossRefGoogle ScholarPubMed
Tsounapi, P, Honda, M, Hikita, K, et al. (2019) Oxidative stress alterations in the bladder of a short-period type 2 diabetes rat model: antioxidant treatment can be beneficial for the bladder. In Vivo 33, 1819–1826.CrossRefGoogle ScholarPubMed
Sehirli, O, Sakarcan, A, Velioglu-Ogunç, A, et al. (2007) Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. Toxicol Appl Pharmacol 222, 33–41.CrossRefGoogle ScholarPubMed
Keles, I, Bozkurt, MF, Cemek, M, et al. (2014) Prevention of cyclophosphamide-induced hemorrhagic cystitis by resveratrol: a comparative experimental study with mesna. Int Urol Nephrol 46, 2301–2310.CrossRefGoogle ScholarPubMed
Francis, JA, Leggett, RE, Schuler, C, et al. (2015) Comparative biochemical responses and antioxidant activities of the rabbit urinary bladder to whole grapes versus resveratrol. Mol Cell Biochem 410, 121–129.CrossRefGoogle ScholarPubMed
Andersson, KE (2018) Oxidative stress and its possible relation to lower urinary tract functional pathology. BJU Int 121, 527–533.CrossRefGoogle ScholarPubMed
Tsuda, Y, Nakahara, T, Mori, A, et al. (2011) Resveratrol prevents bradykinin-induced contraction of rat urinary bladders by decreasing prostaglandin production and calcium influx. Eur J Pharmacol 666, 189–195.CrossRefGoogle ScholarPubMed
Luptak, J, Kocmalova, M, Franova, S, et al. (2018) Involvement of calcium regulating ion channels in contractility of human isolated urinary bladder. Gen Physiol Biophys 37, 391–398.CrossRefGoogle ScholarPubMed
Leiria, LO, Sollon, C, Calixto, MC, et al. (2012) Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. PLoS One 7, e48507.CrossRefGoogle Scholar
Mokbel, K & Wazir, U (2019) Chemoprevention of prostate cancer by natural agents: evidence from molecular and epidemiological studies. Anticancer Res 39, 5231–5259.CrossRefGoogle ScholarPubMed
Devlin, CM, Simms, MS & Maitland, NJ (2021) Benign prostatic hyperplasia – what do we know? BJU Int 127, 389–399.CrossRefGoogle ScholarPubMed
Li, C, Hu, WL, Lu, MX, et al. (2019) Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway. BMC Complement Altern Med 19, 233.CrossRefGoogle ScholarPubMed
Zhang, JJ, Wu, M, Schoene, NW, et al. (2009) Effect of resveratrol and zinc on intracellular zinc status in normal human prostate epithelial cells. Am J Physiol Cell Physiol 297, C632–C644.CrossRefGoogle ScholarPubMed
Chen, Y, Xu, H, Liu, C, et al. (2021) LncRNA DIO3OS regulated by TGF-β1 and resveratrol enhances epithelial mesenchymal transition of benign prostatic hyperplasia epithelial cells and proliferation of prostate stromal cells. Trans Androl Urol 10, 643–653.CrossRefGoogle ScholarPubMed
Gharaee-Kermani, M, Moore, BB & Macoska, JA (2016) Resveratrol-mediated repression and reversion of prostatic myofibroblast phenoconversion. PLoS One 11, e0158357.CrossRefGoogle Scholar
Zhang, J, Zhang, M, Tang, J, et al. (2020) Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis in press.CrossRefGoogle Scholar
Chung, KS, Cheon, SY & An, HJ (2015) Effects of resveratrol on benign prostatic hyperplasia by the regulation of inflammatory and apoptotic proteins. J Nat Prod 78, 689–694.CrossRefGoogle ScholarPubMed
Lundqvist, J, Tringali, C & Oskarsson, A (2017) Resveratrol, piceatannol and analogs inhibit activation of both wild-type and T877A mutant androgen receptor. J Steroid Biochem Mol Biol 174, 161–168.CrossRefGoogle ScholarPubMed
Li, L, Chen, X, Zhu, Q, et al. (2014) Disrupting androgen production of Leydig cells by resveratrol via direct inhibition of human and rat 3β-hydroxysteroid dehydrogenase. Toxicol Lett 226, 14–19.CrossRefGoogle ScholarPubMed
Gacci, M, Corona, G, Vignozzi, L, et al. (2015) Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int 115, 24–31.CrossRefGoogle ScholarPubMed
Conte, A, Kisslinger, A, Procaccini, C, et al. (2016) Convergent effects of resveratrol and PYK2 on prostate cells. Int J Mol Sci 17, 1542.CrossRefGoogle ScholarPubMed
Vikram, A, Jena, GB & Ramarao, P (2010) Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 70, 79–89.CrossRefGoogle Scholar
Liu, Z, Jiang, C, Zhang, J, et al. (2016) Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation of AMP-activated protein kinase and sirtuin 1 activities. J Diabetes 8, 324–335.CrossRefGoogle ScholarPubMed
Song, JH, Hwang, B, Chung, HJ, et al. (2020) Peanut sprout extracts cultivated with fermented sawdust medium inhibits benign prostatic hyperplasia in vitro and in vivo . World J Mens Health 38, 385–396.CrossRefGoogle ScholarPubMed
De Nunzio, C, Presicce, F & Tubaro, A (2016) Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 13, 613–626.CrossRefGoogle ScholarPubMed
Zeng, H, He, Y, Yu, Y, et al. (2018) Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis by mast cell suppression. Mol Med Rep 17, 918–924.Google ScholarPubMed
He, Y, Zeng, HZ, Yu, Y, et al. (2017) Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis. Environ Toxicol Pharmacol 54, 120–124.CrossRefGoogle ScholarPubMed
Qian, X, Gu, Z, Guan, W, et al. (2021) Resveratrol could attenuate prostatic inflammation in rats with oestradiol-induced chronic prostatitis. Andrologia 53, e14004.CrossRefGoogle ScholarPubMed
He, Y, Zeng, H, Yu, Y, et al. (2017) Resveratrol improved the progression of chronic prostatitis via the downregulation of c-kit/SCF by activating Sirt1. J Agric Food Chem 65, 5668–5673.CrossRefGoogle ScholarPubMed
He, Y, Zeng, H, Yu, Y, et al. (2017) Resveratrol improves smooth muscle carcinogenesis in the progression of chronic prostatitis via the downregulation of c-kit/SCF by activating Sirt1. Biomed Pharmacother 95, 161–166.CrossRefGoogle ScholarPubMed
Paulis, G (2018) Inflammatory mechanism and oxidative stress in prostatitis: the possible role of antioxidant therapy. Res Rep Urol 10, 75–87.Google ScholarPubMed
Ashrafizadeh, M, Najafi, M, Orouei, S, et al. (2020) Resveratrol modulates transforming growth factor-beta (TGF-β) signaling pathway for disease therapy: a new insight into pharmacological activities. Biomedicines 8, 261.CrossRefGoogle ScholarPubMed
Zhang, Y, Lu, Y, Ong’achwa, MJ, et al. (2018) Resveratrol inhibits the TGF-β1-induced proliferation of cardiac fibroblast and collagen secretion by downregulating miR-17 in rat. Biomed Res Int 2018, 1–10.Google ScholarPubMed
Rojas, A, Zhang, P, Wang, Y, et al. (2016) A positive TGF-β/c-kit feedback loop drives tumor progression in advanced primary liver cancer. Neoplasia 18, 371–386.CrossRefGoogle ScholarPubMed
Pyo, KH, Lee, YW, Lee, SH, et al. (2017) Preventive effects of resveratrol-enriched extract of peanut sprout on bacteria- and estradiol-induced prostatitis in mice. Nat Prod Commun 12, 73–78.Google ScholarPubMed
Aydogdu, O, Gocun, PU, Aronsson, P, et al. (2021) Prostate-to-bladder cross-sensitization in a model of zymosan-induced chronic pelvic pain syndrome in rats. Prostate 81, 252–260.CrossRefGoogle Scholar
Yu, Y, Jiang, J, He, YI, et al. (2017) Resveratrol improves urinary dysfunction in rats with chronic prostatitis and suppresses the activity of the stem cell factor/c-Kit signaling pathway. Mol Med Rep 16, 1395–1400.CrossRefGoogle ScholarPubMed
He, Y, Zeng, H, Yu, Y, et al. (2017) Resveratrol improved detrusor fibrosis induced by mast cells during progression of chronic prostatitis in rats. Eur J Pharmacol 815, 495–500.CrossRefGoogle ScholarPubMed
Calmasini, FB, Klee, N, Webb, RC, et al. (2019) Impact of immune system activation and vascular impairment on male and female sexual dysfunction. Sex Med Rev 7, 604–613.CrossRefGoogle ScholarPubMed
Silva, FH, Alexandre, EC, Calmasini, FB, et al. (2015) Treatment with metformin improves erectile dysfunction in a murine model of obesity associated with insulin resistance. Urology 86, 423 e421–426.CrossRefGoogle Scholar
Leisegang, K, Henkel, R & Agarwal, A (2019) Obesity and metabolic syndrome associated with systemic inflammation and the impact on the male reproductive system. Am J Reprod Immunol 82, e13178.CrossRefGoogle ScholarPubMed
Murat, N, Korhan, P, Kizer, O, et al. (2016) Resveratrol protects and restores endothelium-dependent relaxation in hypercholesterolemic rabbit corpus cavernosum. J Sex Med 13, 12–21.CrossRefGoogle ScholarPubMed
Soner, BC, Murat, N, Demir, O, et al. (2010) Evaluation of vascular smooth muscle and corpus cavernosum on hypercholesterolemia. Is resveratrol promising on erectile dysfunction? Int J Impot Res 22, 227–233.CrossRefGoogle ScholarPubMed
Bai, Y & An, R (2015) Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats. Life Sci 135, 43–48.CrossRefGoogle ScholarPubMed
Fukuhara, S, Tsujimura, A, Okuda, H, et al. (2011) Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings. J Sex Med 8, 1061–1071.CrossRefGoogle ScholarPubMed
Dalaklioglu, S, Bayram, Z, Tasatargil, A, et al. (2017) Resveratrol reverses diabetes-related decrement in sildenafil-induced relaxation of corpus cavernosum in aged rats. Aging Clin Exp Res 29, 345–351.CrossRefGoogle ScholarPubMed
Boydens, C, Pauwels, B, Decaluwé, K, et al. (2016) Protective effect of resveratrol and quercetin on in vitro-induced diabetic mouse corpus cavernosum. Cardiovasc Diabetol 15, 46.CrossRefGoogle ScholarPubMed
Donato, AJ, Magerko, KA, Lawson, B, et al. (2011) SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol 589, 4545–4554.CrossRefGoogle ScholarPubMed
Freitas, M, Rodrigues, AR, Tomada, N, et al. (2015) Effects of aging and cardiovascular disease risk factors on the expression of sirtuins in the human corpus cavernosum. J Sex Med 12, 2141–2152.CrossRefGoogle ScholarPubMed
Yu, W, Wan, Z, Qiu, XF, et al. (2013) Resveratrol, an activator of SIRT1, restores erectile function in streptozotocin-induced diabetic rats. Asian J Androl 15, 646–651.CrossRefGoogle ScholarPubMed
Sener, TE, Tavukcu, HH, Atasoy, BM, et al. (2018) Resveratrol treatment may preserve the erectile function after radiotherapy by restoring antioxidant defence mechanisms, SIRT1 and NOS protein expressions. Int J Impot Res 30, 179–188.CrossRefGoogle ScholarPubMed
Yetik-Anacak, G, Dereli, MV, Sevin, G, et al. (2015) Resveratrol stimulates hydrogen sulfide (H2S) formation to relax murine corpus cavernosum. J Sex Med 12, 2004–2012.CrossRefGoogle ScholarPubMed
Sergides, C, Chirila, M, Silvestro, L, et al. (2016) Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Exp Ther Med 11, 164–170.CrossRefGoogle ScholarPubMed
Crozier, A, Jaganath, IB & Clifford, MN (2009) Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26, 1001–1043.CrossRefGoogle ScholarPubMed
Boocock, DJ, Patel, KR, Faust, G, et al. (2007) Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 848, 182–187.CrossRefGoogle ScholarPubMed
Emília, JM, Buenafuente, J & Casals, I (2002) Plasmatic levels of trans-resveratrol in rats. Food Res Int 35, 195–199.CrossRefGoogle Scholar
Marier, JF, Vachon, P, Gritsas, A, et al. (2002) Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302, 369–373.CrossRefGoogle ScholarPubMed
Huang, Y, Lang, H, Chen, K, et al. (2020) Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway. Appl Physiol Nutr Metab 45, 227–239.CrossRefGoogle ScholarPubMed
Cote, CD, Rasmussen, BA, Duca, FA, et al. (2015) Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat Med 21, 498–505.CrossRefGoogle ScholarPubMed
Man, AWC, Huige, L & Ning, X (2020) Resveratrol and the interaction between gut microbiota and arterial remodeling. Nutrients 12, 119.CrossRefGoogle Scholar
Hernández-Ceballos, W, Cordova-Gallardo, J & Mendez-Sanchez, N (2021) Gut microbiota in metabolic-associated fatty liver disease and in other chronic metabolic diseases. J Clin Transl Hepatol 9, 227–238.Google ScholarPubMed
Chaplin, A, Carpéné, C & Mercader, J (2018) Resveratrol, metabolic syndrome, and gut microbiota. Nutrients 10, 1651.CrossRefGoogle ScholarPubMed
Qiao, Y, Sun, J, Xia, S, et al. (2014) Effects of resveratrol on UGT microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct 5, 1241–1249.CrossRefGoogle Scholar
Hui, S, Liu, Y, Huang, L, et al. (2020) Resveratrol enhances brown adipose tissue activity and white adipose tissue browning in part by regulating bile acid metabolism via gut microbiota remodeling. Int J Obes 44, 1678–1690.CrossRefGoogle ScholarPubMed
Kim, TT, Parajuli, N, Sung, MM, et al. (2018) Fecal transplant from resveratrol-fed donors improves glycaemia and cardiovascular features of the metabolic syndrome in mice. Am J Physiol Endocrinol Metab 315, E511–E519.CrossRefGoogle ScholarPubMed
Roje, B, Elek, A, Palada, V, et al. (2020) Microbiota alters urinary bladder weight and gene expression. Microorganisms 8, 421.CrossRefGoogle ScholarPubMed
Okamoto, T, Hatakeyama, S, Imai, A, et al. (2020) Altered UGT microbiome associated with overactive bladder and daily urinary urgency. World J Urol in print.CrossRefGoogle Scholar
Holland, B, Karr, M, Delfino, K, et al. (2020) The effect of the urinary and faecal microbiota on lower urinary tract symptoms measured by the International Prostate Symptom Score: analysis utilising next-generation sequencing. BJU Int 125, 905–910.Google ScholarPubMed
Noronha, R, Akbarali, H, Malykhina, A, et al. (2007) Changes in urinary bladder smooth muscle function in response to colonic inflammation. Am J Physiol Renal Physiol 293, F1461–F1467.CrossRefGoogle ScholarPubMed
Hsu, CY, Lin, CL & Kao, C (2015) Irritable bowel syndrome is associated not only with organic but also psychogenic erectile dysfunction. Int J Impot Res 27, 233–238.CrossRefGoogle Scholar
Cani, PD & Knauf, C (2016) How gut microbes talk to organs: the role of endocrine and nervous routes. Mol Metab 5, 743–752.CrossRefGoogle ScholarPubMed
Kjær, TN, Ornstrup, MJ, Poulsen, MM, et al. (2015) Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men. Prostate 75, 1255–1263.CrossRefGoogle ScholarPubMed
Vicari, E, Arancio, A, Catania, VE, et al. (2020) Resveratrol reduces inflammation-related prostate fibrosis. Int J Med Sci 17, 1864–1870.CrossRefGoogle ScholarPubMed
Liang, L, Liu, X, Wang, Q, et al. (2013) Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. Phytomedicine 20, 558–563.CrossRefGoogle ScholarPubMed
Hussain, SA, Marouf, BH, Ali, ZS, et al. (2018) Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study. Clin Interv Aging 13, 1621–1630.CrossRefGoogle ScholarPubMed
Amiot, MJ, Romier, B, Anh, T, et al. (2013) Optimization of trans-resveratrol bioavailability for human therapy. Biochimie 95, 1233–1238.CrossRefGoogle ScholarPubMed
la Porte, C, Voduc, N, Zhang, G, et al. (2010) Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 49, 449–454.CrossRefGoogle ScholarPubMed
Ha, ES, Sim, WY, Lee, S, et al. (2019) Preparation and evaluation of resveratrol-loaded composite nanoparticles using a supercritical fluid technology for enhanced oral and skin delivery. Antioxidants (Basel) 8, 554.CrossRefGoogle ScholarPubMed
Barbosa, C, Santos-Pereira, C, Soares, I, et al. (2019) Resveratrol-loaded lipid nanocarriers are internalized by endocytosis in yeast. J Nat Prod 82, 1240–1249.CrossRefGoogle ScholarPubMed
He, Y, Zeng, H, Yu, Y, et al. (2017) Resveratrol improves cell cycle arrest in chronic prostatitis via the downregulation of c-kit/SCF by activating sirt-1. DNA Cell Biol 36, 709–714.CrossRefGoogle Scholar
Cardoso, HJ, Figueira, MI, Correia, SV, et al. (2014) The SCF/c-KIT system in the male: survival strategies in fertility and cancer. Mol Rep Dev 81, 1064–1079.CrossRefGoogle ScholarPubMed
Imura, M, Kojima, Y, Kubota, Y, et al. (2012) Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia. Prostate 72, 1506–1513.CrossRefGoogle ScholarPubMed
Baksi, A, Kraydashenko, O, Zalevkaya, A, et al. (2014) A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. Br J Clin Pharmacol 78, 69–77.CrossRefGoogle ScholarPubMed